Key facts
- CounterX Therapeutics will present at the 88th Annual College on Problems of Drug Dependence Scientific Meeting.
- The presentation will focus on CTRX-101, a once-monthly monoclonal antibody for fentanyl overdose prevention.
- Company leadership will also discuss CounterX Therapeutics' pipeline.
CounterX Therapeutics, a biotechnology company focused on developing novel drug candidates, is scheduled to present at the 88th Annual College on Problems of Drug Dependence (CPDD) Scientific Meeting. The presentation will feature updates on CTRX-101, a novel monoclonal antibody designed for the once-monthly prevention of fentanyl overdose. Additionally, company leadership will provide an overview of CounterX Therapeutics' pipeline of drug candidates.